Current status of red blood cell manufacturing in 3D culture and bioreactors

Owing to donor-related issues, blood shortages and transfusion-related adverse reactions have become global issues of grave concern. In vitro manufactured red blood cells (RBCs) are promising substitutes for blood donation. In the United Kingdom, a clinical trial for allogeneic mini transfusion of cultured RBCs derived from primary hematopoietic stem cells has recently begun. However, current production quantities are limited and need improved before clinical use. New methods to enhance manufacturing efficiencies have been explored, including different cell sources, bioreactors, and 3-dimensional (3D) materials; however, further research is required. In this review, we discuss various cell sources for blood cell production, recent advances in bioreactor manufacturing processes, and the clinical applications of cultured blood.

Automated summary

Due to donor-related issues, blood shortages and transfusion-related adverse reactions have become global concerns. In vitro manufactured red blood cells (RBCs) show promise as substitutes for blood donation. However, current production quantities are limited and need improvement for clinical use. This review discusses various cell sources for blood cell production, recent advances in bioreactor manufacturing processes, and the clinical applications of cultured blood.